`
`______________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`______________________
`
`
`
`MYLAN PHARMACEUTICALS INC.,
`WOCKHARDT BIO AG,
`TEVA PHARMACEUTICALS USA, INC.,
`AUROBINDO PHARMA U.S.A., INC.,
`Petitioners,
`
`v.
`
`ASTRAZENECA AB,
`Patent Owner.
`
`
`
`Case: IPR2015-013401
`U.S. Patent No. RE44,186
`
`
`ASTRAZENECA’S NOTICE OF DEPOSITION OF
`DR. ROBERT J. TANENBERG
`
`
`
`
`
`
`
`
`
`1 Petitioner Wockhardt from IPR2016-01029, Petitioner Teva from IPR2016-
`01122, and Petitioner Aurobindo from IPR2016-01117 have been added as
`Petitioners to this proceeding.
`
`
`
`
`
`Pursuant to 37 C.F.R. § 42.53, Patent Owner AstraZeneca hereby provides
`
`Case IPR2015-01340
`U.S. Patent No. RE44,186
`
`
`
`
`notice that it will take the deposition of Dr. Robert J. Tanenberg, a reply witness of
`
`Petitioner Mylan Pharmaceuticals Inc. The deposition will take place on
`
`December 2, 2016 at 9:00 am at Hilton Greenville, 207 SW Greenville Blvd.,
`
`Greenville, North Carolina 27834 or at some other mutually convenient time and
`
`location. The deposition will take place before a Notary Public or other officer
`
`authorized by law to administer oaths, to be arranged for by counsel for
`
`AstraZeneca. The direct examination will be recorded using stenographic means
`
`Respectfully submitted,
`
`only.
`
`Dated: November 21, 2016
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`By: /Anthony A. Hartmann/
`Anthony A. Hartmann, Reg. No. 43,662
`anthony.hartmann@finnegan.com
`Finnegan, Henderson, Farabow,
`Garrett & Dunner, L.L.P.
`901 New York Avenue, NW
`Washington, DC 20001
`Tel: 202-408-4275
`Fax: 202-208-4400
`
`Counsel for Patent Owner
`
`
`
`
`
`2
`
`
`
`Case IPR2015-01340
`U.S. Patent No. RE44,186
`
`CERTIFICATE OF SERVICE
`
`The undersigned certifies that copies of the foregoing ASTRAZENECA’S
`
`
`
`
`
`
`NOTICE OF DEPOSITION OF DR. ROBERT J. TANENBERG was served
`
`electronically via e-mail on November 21, 2016, in its entirety to the following:
`
`Counsel for Petitioner Mylan Pharmaceuticals Inc.:
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Steven W. Parmelee
`sparmelee@wsgr.com
`
`Richard Torczon
`rtorczon@wsgr.com
`
`Jad A. Mills
`jmills@wsgr.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Douglas H. Carsten
`dcarsten@wsgr.com
`
`
`
`Counsel for Petitioner Wockhardt BIO AG.:
`
`
`
`
`
`Counsel for Petitioner Teva Pharmaceuticals U.S.A., Inc..:
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Patrick Gallagher
`PCGallagher@duanemorris.com
`
`Gary Speier
`gspeier@carlsoncaspers.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Iain McIntyre
`imcintyre@carlsoncaspers.com
`
`3
`
`
`
`
`
`
`
`
`
`
`Counsel for Petitioner Aurobindo Pharma U.S.A., Inc..:
`
`Case IPR2015-01340
`U.S. Patent No. RE44,186
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Sailesh K. Patel
`SPatel@schiffhardin.com
`
`George Yu
`GYu@schiffhardin.com
`
`By: /Lauren K. Young/
`Lauren K. Young
`Litigation Legal Assistant
`FINNEGAN, HENDERSON, FARABOW,
`GARRETT & DUNNER, L.L.P.
`
`
`4
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Dated: November 21, 2016